Whitehawk Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M |
| Operating income | -$114.4M | -$67.5M | -$71.9M | -$62.7M | -$111.2M |
| Operating expenses | — | — | — | — | $112.3M |
| Cost of revenue | $760,000 | $3.0M | $2.8M | $1.3M | $0 |
| Cash from operations | -$97.4M | -$59.5M | -$59.7M | -$49.6M | -$22.4M |
| Capital expenditure | $552,000 | $1.7M | $4.0M | $444,000 | $46,000 |
| Free cash flow | -$98.0M | -$61.2M | -$63.6M | -$50.1M | -$22.5M |
| Impairments | — | — | $0 | $3.7M | $74.2M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M |
Shares outstanding 49.5M · Free float 38.9%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.